A prostate biopsy is a procedure that removes small cores of tissue from the prostate so a pathologist can examine the cells and glandular architecture under a microscope. It is the test that usually establishes whether prostate cancer is actually present and, when cancer is found, provides information such as Gleason pattern, ISUP Grade Group, the amount of cancer in sampled cores and other pathological features that cannot be determined from PSA or MRI alone. Biopsy needles may enter the prostate through the perineal skin or through the rectal wall, and the sampling strategy may be systematic, MRI-targeted, perilesional or a combination selected for the clinical situation.
A prostate biopsy is generally performed when the probability of clinically significant prostate cancer remains high enough after PSA, examination, MRI and other risk assessment to justify tissue diagnosis. Modern pathways increasingly use prostate MRI before biopsy so that suspicious prostate lesions can be targeted. Current EAU guidance prefers the transperineal route because of its lower infectious risk and advantages for antibiotic stewardship, although other guidelines, including AUA guidance, recognize both transperineal and transrectal biopsy as established routes.
01Why Is a Prostate Biopsy Performed and What Can It Diagnose?
Biopsy answers a question that PSA and MRI cannot answer definitively
PSA, digital rectal examination and MRI are probability tools.
They can indicate that prostate cancer is more or less likely, but none can reliably show the microscopic architecture needed to establish:
- whether malignant prostate glands are present;
- which histological type of cancer is present;
- the Gleason patterns;
- the ISUP Grade Group;
- the amount of tumor in sampled cores;
- and selected adverse pathological features.
That is why biopsy sits at the transition between cancer suspicion and tissue diagnosis.
When does an elevated PSA lead to biopsy?
Not every high PSA should immediately produce a biopsy.
A modern diagnostic pathway may first include:
- confirmation of an unexpectedly elevated PSA;
- review of benign and temporary causes of PSA elevation;
- digital rectal examination;
- prostate volume measurement;
- PSA density;
- risk calculators or selected additional biomarkers;
- family and genetic risk;
- and prostate MRI.
The broader sequence is explained in How Prostate Cancer Is Diagnosed.
Does every abnormal MRI need biopsy?
No.
The MRI result is interpreted together with the rest of the clinical risk.
Current EAU guidance allows biopsy to be omitted with PSA monitoring in selected men when:
- MRI is negative, generally PI-RADS 1–2;
- PSA density is below approximately 0.20 ng/mL/cc;
- and there is no important prostate-cancer family history.
For an indeterminate PI-RADS 3 lesion, biopsy can also sometimes be avoided when overall suspicion is very low, including PSA density below approximately 0.10 ng/mL/cc and no important family history.
Those are risk-directed decisions, not universal thresholds.
What usually happens with PI-RADS 4 or 5?
A lesion scored PI-RADS 4 or 5 has sufficiently suspicious MRI characteristics that biopsy is generally considered appropriate when a man is undergoing diagnostic evaluation.
Current EAU guidance recommends targeted biopsy plus perilesional sampling for MRI-positive lesions scored PI-RADS 4 or higher.
Can a normal PSA still lead to biopsy?
Yes.
PSA is not perfectly sensitive for clinically significant prostate cancer.
Biopsy may still be considered when other findings are sufficiently concerning, such as:
- a clearly suspicious prostate nodule on DRE;
- a high-suspicion MRI lesion;
- strong hereditary risk;
- or continuing clinical concern despite PSA values that are not markedly elevated.
The clinical meaning of an abnormal examination is explained in What Is a Prostate Nodule?.
Can a high PSA be followed without biopsy?
Yes in selected situations.
A high PSA can arise from:
- BPH;
- prostatitis;
- urinary retention;
- recent urinary or prostate procedures;
- and other benign influences.
The diagnostic pathway may therefore include repeat PSA and risk refinement before invasive sampling.
See High PSA Without Prostate Cancer and What Happens After a High PSA?.
Can biopsy diagnose conditions other than cancer?
Yes.
A cancer-negative biopsy may show:
- benign prostatic tissue;
- benign hyperplasia;
- acute or chronic inflammation;
- granulomatous inflammation;
- atrophy;
- fibromuscular or stromal change;
- or atypical findings that require specific follow-up.
Current EAU pathology recommendations specifically encourage reporting a meaningful benign diagnosis when an MRI-targeted core is cancer-negative rather than simply labeling every sample “negative.”
The biopsy decision should occur before the needle does. The central question is whether tissue information is likely to change diagnosis or management. Age, comorbidity, life expectancy, MRI, PSA density, hereditary risk and the consequences of finding cancer all belong in that discussion.
02How Is a Prostate Biopsy Performed? Transperineal, Transrectal and MRI-Targeted Methods
Biopsy route and biopsy strategy are different concepts
Two questions are often mixed together:
Route: How does the needle physically reach the prostate?
Strategy: Which parts of the prostate are sampled once the needle is there?
A biopsy can therefore be:
- transperineal and MRI-targeted;
- transperineal and systematic;
- transperineal targeted plus perilesional;
- transrectal and MRI-targeted;
- or another combination appropriate for the diagnostic purpose.
What is a transperineal prostate biopsy?
In a transperineal biopsy, the needle enters through disinfected skin in the perineum—the area between the scrotum and anus—and then passes into the prostate.
Real-time ultrasound is commonly used to visualize the gland and guide needle placement.
MRI targets can be incorporated through:
- cognitive targeting;
- MRI-ultrasound fusion software;
- or other image-guidance systems.
Why has transperineal biopsy become increasingly favored?
The needle does not pass through the rectal wall.
This substantially reduces exposure to rectal bacteria.
Current EAU guidance gives a strong recommendation for the transperineal route because of:
- lower infectious complications;
- better antibiotic stewardship;
- and the ability to perform the procedure under local anesthesia in modern practice.
Transperineal access can also provide useful sampling of anterior parts of the prostate.
Does transperineal biopsy always require general anesthesia?
No.
Historically, template transperineal procedures were often performed under general or spinal anesthesia.
Modern freehand and grid-based techniques can be performed under local anesthesia in many centers.
The exact anesthesia plan depends on:
- the number of samples;
- local technique;
- prostate anatomy;
- patient comfort;
- and institutional practice.
What is a transrectal prostate biopsy?
In a transrectal biopsy, an ultrasound probe is placed in the rectum and the biopsy needle passes through the rectal wall into the prostate.
This route has decades of clinical experience and can also be used for:
- systematic sampling;
- cognitive MRI targeting;
- and MRI-ultrasound fusion biopsy.
Is transrectal biopsy still an accepted method?
Yes, but current guideline emphasis differs.
EAU guidance now prefers transperineal biopsy because of infection prevention and antibiotic stewardship.
The AUA/SUO early-detection guideline states that clinicians may use either the transrectal or transperineal route.
This is an example where different guideline systems place different weight on the same evidence rather than one route being technically impossible or universally inappropriate.
What infection precautions are used with transrectal biopsy?
Because the needle passes through rectal flora, infection prevention is particularly important.
Current EAU recommendations include:
- rectal cleansing with povidone-iodine before transrectal biopsy;
- appropriate antimicrobial prophylaxis;
- and, where applicable, culture-directed or augmented antibiotic strategies consistent with local resistance patterns and regulations.
Antibiotic selection should follow local guidance rather than a universal drug regimen.
What is a systematic prostate biopsy?
A systematic biopsy samples predetermined anatomical regions whether or not a specific lesion is visible.
When biopsy is performed without an MRI-defined target, EAU guidance states that systematic cores should be taken:
- bilaterally;
- from apex to base;
- as posteriorly and laterally as practical in the peripheral gland.
Historical evidence supports approximately 12 cores as the minimum standard systematic set; taking more than 12 routine systematic cores does not necessarily increase cancer detection enough to justify indiscriminate extra sampling.
What is an MRI-targeted biopsy?
An MRI-targeted biopsy directs one or more biopsy cores specifically into a lesion identified on MRI.
Targeting can be performed in three main ways:
- Cognitive targeting: the operator reviews the MRI and mentally maps the lesion onto real-time ultrasound.
- MRI-ultrasound software fusion: software aligns the prior MRI with live ultrasound.
- Direct in-bore MRI biopsy: the target is sampled while the patient remains within an MRI-guided procedure.
Is fusion biopsy more accurate than cognitive targeting?
Not universally.
EAU evidence has not established clear superiority of cognitive targeting, software fusion or direct in-bore targeting across all clinical settings.
Operator skill, MRI quality, lesion location and local technology all influence performance.
How many cores are taken from an MRI target?
The exact number depends on:
- lesion size;
- lesion location;
- targeting system;
- sampling strategy;
- and whether surrounding tissue is also being sampled.
AUA guidance recommends obtaining at least two needle cores per suspicious MRI target.
Current European practice increasingly emphasizes targeted cores plus sampling immediately around the lesion rather than assuming the MRI boundary perfectly represents the microscopic tumor boundary.
What is perilesional biopsy?
Perilesional sampling takes cores from tissue immediately adjacent to the MRI target.
This is important because:
- MRI can underestimate tumor size;
- software registration is not perfectly exact;
- the needle can deviate slightly from the planned trajectory;
- and aggressive tissue may extend beyond the most conspicuous MRI focus.
Is systematic biopsy still needed when MRI shows a target?
This has become more nuanced.
Older MRI-era comparisons showed that targeted biopsy improves detection of clinically significant cancer and reduces detection of low-grade disease compared with systematic biopsy alone.
However, systematic sampling can still find some clinically significant cancers outside MRI targets.
Current approaches therefore vary according to:
- whether the man has had a previous biopsy;
- PI-RADS score;
- number of lesions;
- PSA density;
- whether the purpose is simply cancer diagnosis or detailed treatment planning;
- and local guideline practice.
The 2026 ProBIOPSY international consensus supports contemporary targeted and perilesional strategies for many situations but emphasizes that no single biopsy scheme provides all information needed for every treatment decision.
Why might treatment planning require additional sampling?
The diagnostic question can change after cancer is suspected.
For example, a man being considered for focal therapy may need evidence about tissue outside the dominant MRI target because treatment is intentionally limited to part of the prostate.
The 2026 ProBIOPSY consensus specifically notes that additional contralateral sampling can remain important for selected indications such as focal-therapy candidate assessment.
Biopsy strategy is becoming indication-specific. A man undergoing his first diagnostic biopsy, a man with a previous negative biopsy, and a man being evaluated for focal therapy may need different sampling patterns even when the MRI lesion looks identical.
03What Happens to Prostate Biopsy Tissue and What Does the Pathology Report Show?
The biopsy is only the beginning of the diagnostic test
Once the tissue cores are removed, they are sent to pathology.
The laboratory:
- fixes the tissue;
- places cores into processing cassettes;
- embeds the tissue in paraffin;
- cuts extremely thin sections;
- places the sections on glass slides;
- stains them, usually with hematoxylin and eosin;
- and examines the architecture under a microscope.
What does the pathologist look for?
The central question is whether the normal prostate glandular architecture has been replaced by malignant glands.
The pathologist assesses:
- gland shape and arrangement;
- cellular appearance;
- relationship between glands and stroma;
- loss of normal basal-cell architecture;
- infiltrative growth;
- and, when needed, immunohistochemical markers.
What if prostate cancer is found?
The pathology report should provide more than a simple “positive.”
Current EAU recommendations include reporting:
- type of carcinoma;
- primary and secondary Gleason patterns for each biopsy site;
- ISUP Grade Group;
- percentage Gleason pattern 4 in Gleason score 7 biopsies;
- presence or absence of intraductal carcinoma and invasive cribriform carcinoma;
- number of cancer-positive cores;
- extent of cancer in millimeters or percentage;
- and, where present, lymphovascular invasion, extraprostatic extension or seminal-vesicle/ejaculatory-duct involvement.
How are MRI-targeted cores reported?
When several cores come from the same MRI lesion, pathology can report an aggregate or composite Grade Group for that target.
This preserves the relationship between:
- the MRI lesion;
- the biopsy site;
- and the microscopic cancer grade.
What is the Gleason score?
Gleason grading describes the microscopic architecture of prostate adenocarcinoma.
In contemporary biopsy reporting, the two dominant malignant architectural patterns are assigned pattern grades, usually from 3 through 5.
They are combined into scores such as:
- 3 + 3 = 6;
- 3 + 4 = 7;
- 4 + 3 = 7;
- 4 + 4 = 8;
- 4 + 5 = 9;
- or 5 + 5 = 10.
Why are Gleason 3+4 and 4+3 different?
Both total 7 mathematically, but their biology is not equivalent.
In 3+4 cancer, pattern 3 is predominant and pattern 4 is secondary.
In 4+3 cancer, the more aggressive pattern 4 architecture predominates.
That difference is reflected in ISUP Grade Groups.
What are ISUP Grade Groups?
| Grade Group | Typical Gleason score | General pathological interpretation |
|---|---|---|
| 1 | 3 + 3 = 6 | Lowest contemporary prostate adenocarcinoma grade group. |
| 2 | 3 + 4 = 7 | Predominantly pattern 3 with a smaller pattern 4 component. |
| 3 | 4 + 3 = 7 | Pattern 4 predominates, carrying greater biological risk than 3+4. |
| 4 | 8 | High-grade architecture, including combinations that total Gleason 8. |
| 5 | 9–10 | Highest contemporary Grade Group, reflecting very high-grade architecture. |
Does Grade Group tell the cancer stage?
No.
Grade describes microscopic architecture and biological aggressiveness.
Stage describes the anatomical extent of cancer.
A biopsy therefore contributes strongly to risk assessment but does not independently establish the full stage.
What does “percentage pattern 4” mean?
For Gleason score 7 cancers, the proportion of higher-grade pattern 4 tissue can influence risk interpretation.
A small pattern-4 component in a 3+4 tumor is biologically different from a cancer composed predominantly of pattern 4.
This is one reason modern pathology reports provide more granularity than the total Gleason number alone.
Why do cribriform and intraductal findings matter?
Cribriform architecture and intraductal carcinoma are adverse pathological features associated with more aggressive disease behavior.
Current EAU recommendations specifically call for their presence or absence to be documented because they can influence risk classification and management discussions.
What does “core involvement” mean?
Pathologists can report:
- how many cores contain cancer;
- the length of cancer within a core;
- or the percentage of that core involved.
This gives an estimate of sampled tumor burden.
It does not represent the exact percentage of the entire prostate occupied by cancer.
What if the biopsy is negative?
A negative biopsy means cancer was not identified in the submitted tissue.
It does not automatically mean:
- the entire prostate is cancer-free;
- the MRI lesion was meaningless;
- or future follow-up is unnecessary.
Why can biopsy miss cancer?
A biopsy samples a small fraction of the prostate.
False-negative results can occur because:
- the needle passed beside the tumor;
- registration between MRI and ultrasound was imperfect;
- the tumor extended outside the apparent MRI target;
- the lesion was small;
- or the cancer existed in an unsampled region.
What if PI-RADS 4 or 5 is biopsy-negative?
Persistent discordance deserves review rather than automatic reassurance.
Depending on overall risk, clinicians may consider:
- review of MRI quality and interpretation;
- review of biopsy pathology;
- repeat PSA and PSA density;
- repeat MRI;
- or repeat targeted biopsy.
A negative needle biopsy is a sampling result, not an anatomical scan of every prostate cell. Its reassurance depends on how well the suspicious region was sampled, the underlying MRI and PSA risk, and whether the findings remain concordant over time.
04What Happens Before and After a Prostate Biopsy, and What Are the Main Risks?
Preparation depends on the route, anesthesia and medical history
Instructions vary between centers, but pre-biopsy assessment commonly includes review of:
- blood-thinning medication;
- antiplatelet medication;
- bleeding disorders;
- drug allergies;
- urinary infection symptoms;
- previous resistant infections;
- implanted devices or other relevant medical conditions;
- and the anesthesia plan.
Do not independently stop anticoagulants or antiplatelet medicines before biopsy. Medicines such as warfarin, apixaban, rivaroxaban, clopidogrel or aspirin require individualized instructions because stopping them can itself create serious cardiovascular or clotting risk.
What if a urinary infection is present?
An active urinary infection can increase biopsy-related infectious risk.
When infection is suspected, urine testing and treatment may be needed before an elective biopsy proceeds.
Are antibiotics always needed?
Not necessarily for every biopsy route and every patient.
EAU guidance now states that antibiotic prophylaxis can be omitted in selected patients undergoing transperineal biopsy who do not have risk factors for infectious complications.
Transrectal biopsy requires stronger infection-prevention measures because the needle passes through rectal bacteria.
Local practice should follow the center’s current infection-control protocol rather than a generic internet antibiotic regimen.
What type of anesthesia is used?
Both transperineal and transrectal biopsy can be performed under local anesthesia.
Depending on the center and extent of sampling, options can include:
- local skin infiltration;
- periprostatic nerve block;
- additional perineal nerve block;
- sedation;
- or general anesthesia in selected procedures.
What does the procedure feel like?
Patients commonly describe:
- pressure from the ultrasound probe;
- brief needle clicks;
- pressure or pinching during local-anesthetic injections;
- and short-lived discomfort as cores are taken.
Pain experience varies substantially.
Good local anesthesia and communication during the procedure are important parts of biopsy quality.
Is blood in the urine normal after biopsy?
A small amount of blood in the urine is common after prostate biopsy.
It usually improves without intervention.
The exact duration varies according to:
- number of cores;
- route;
- medications;
- individual bleeding tendency;
- and prostate anatomy.
Is blood in semen normal after biopsy?
Yes.
Hematospermia is common because biopsy needles pass through vascular prostate tissue involved in seminal fluid production.
Semen may appear:
- red;
- dark red;
- brown;
- or rust-colored
for several ejaculations and sometimes for several weeks.
Old blood becoming brown does not necessarily indicate new bleeding.
Can prostate biopsy cause rectal bleeding?
Rectal bleeding is more relevant after transrectal biopsy because the needle crosses the rectal wall.
Minor short-lived bleeding can occur.
Heavy or persistent bleeding requires medical attention.
Can prostate biopsy cause urinary retention?
Yes.
Biopsy can cause temporary prostate swelling and bleeding around the urethra.
A small proportion of men become unable to urinate and require temporary catheter drainage.
Risk may be higher with:
- large prostates;
- pre-existing obstructive urinary symptoms;
- greater numbers of cores;
- and more extensive template sampling.
Can biopsy cause infection or sepsis?
Yes, although risk varies substantially by route.
The transperineal approach has a lower infectious risk because the needle avoids the rectal lumen.
Transrectal biopsy carries greater exposure to bowel bacteria and therefore requires specific infection-prevention measures.
Any post-biopsy fever, rigors or systemic illness should be treated seriously.
Does prostate biopsy spread cancer?
Routine prostate needle biopsy has not been shown to meaningfully cause prostate cancer to spread through the body.
Rare needle-tract tumor seeding has been described in isolated reports, but this is considered an exceptional event rather than a routine clinical risk that outweighs the diagnostic benefit of an appropriately indicated biopsy.
Can biopsy cause erectile dysfunction?
Temporary erectile changes have been reported after prostate biopsy in some men.
Possible contributors include:
- pain;
- anxiety;
- inflammation;
- pelvic discomfort;
- and transient local effects.
Persistent erectile dysfunction is not considered an expected outcome of a routine biopsy, but individual experiences vary.
When should someone seek urgent help after biopsy?
Seek prompt medical assessment for:
- fever or shaking chills;
- feeling severely unwell;
- inability to urinate;
- heavy or persistent bleeding;
- large blood clots;
- progressively worsening pelvic pain;
- dizziness, faintness or signs of substantial blood loss.
How long does pathology take?
Turnaround varies by laboratory.
Additional time may be required when:
- deeper tissue sections are needed;
- immunohistochemistry is required;
- another pathologist reviews the case;
- or specialized pathological features need clarification.
The clinically important point is to wait for the finalized pathology report rather than interpreting the number of cores or MRI score as if they already provide the histological answer.
What happens if cancer is found?
The next stage is not automatically treatment.
Clinicians first integrate:
- Grade Group;
- PSA;
- amount of cancer in biopsy cores;
- MRI and local stage;
- additional staging imaging when indicated;
- age and overall health;
- and patient priorities.
Some lower-risk cancers may be appropriate for active surveillance, whereas higher-risk or more extensive disease may require different treatment discussions.
The broader disease pathway is organized in the Prostate Cancer hub.
What happens if cancer is not found?
The answer depends on why the biopsy was performed.
If PSA, DRE and MRI become reassuring, continued monitoring may be reasonable.
If a highly suspicious lesion or adverse PSA pattern persists, clinicians may reconsider:
- MRI interpretation;
- biopsy targeting quality;
- pathology review;
- repeat MRI;
- or repeat biopsy.
The result should close the loop with the original reason for biopsy. A negative biopsy after a low-risk equivocal MRI carries a different meaning from a negative biopsy of a persistent PI-RADS 5 lesion with high PSA density.
→Prostate Biopsy Methods Compared
| Method | What it describes | Main strength | Main limitation or consideration |
|---|---|---|---|
| Transperineal biopsy | Needle enters through perineal skin. | Lower infectious risk; good access to anterior prostate; increasingly preferred by EAU. | Requires perineal anesthesia and operator familiarity; urinary retention can still occur. |
| Transrectal biopsy | Needle passes through rectal wall. | Established technique with widespread expertise and ultrasound access. | Greater exposure to rectal bacteria and greater emphasis on antibiotic/infection prevention. |
| Systematic biopsy | Samples predetermined prostate regions. | Can detect cancer outside visible MRI targets. | May sample more benign tissue and detect more low-grade disease. |
| MRI-targeted biopsy | Samples a lesion previously identified on MRI. | Improves sampling of clinically significant MRI-visible cancer. | Depends on MRI quality, targeting accuracy and operator experience. |
| Perilesional biopsy | Samples tissue immediately around the MRI target. | Accounts for targeting error and underestimation of lesion boundaries. | Exact spatial strategy is not perfectly standardized across all centers. |
| Cognitive targeting | Operator mentally transfers MRI location to live ultrasound. | No dedicated fusion platform required. | Highly dependent on operator spatial interpretation and experience. |
| MRI-ultrasound fusion | Software aligns MRI with live ultrasound. | Creates visible digital target registration. | Registration remains imperfect and software has not proven universally superior to all other methods. |
| In-bore MRI biopsy | Target sampled under direct MRI guidance. | Direct visualization of target during biopsy. | Resource intensive and available in fewer centers. |
| Saturation / template biopsy | Large number of cores, often more than 20. | Can extensively map the gland in selected repeat-biopsy or treatment-planning settings. | Not routinely needed in the modern MRI pathway; more extensive sampling can increase procedure burden and retention risk. |
?Common Questions About Prostate Biopsy
| Question | Practical answer |
|---|---|
| What is a prostate biopsy? | A procedure that removes small prostate tissue cores so a pathologist can examine them microscopically for cancer and other abnormalities. |
| Does a prostate biopsy diagnose cancer? | Yes. Needle-biopsy pathology is the usual method for establishing a prostate-cancer diagnosis. |
| Can PSA diagnose prostate cancer without biopsy? | No. PSA changes cancer probability but is not cancer-specific. |
| Can MRI diagnose prostate cancer without biopsy? | MRI can show highly suspicious lesions, but tissue is usually required to confirm cancer and establish Grade Group. |
| Does every high PSA need biopsy? | No. PSA can be repeated and interpreted with prostate volume, PSA density, MRI, DRE, family history and other risk information. |
| Does every PI-RADS 3 lesion need biopsy? | No. Selected men with very low PSA density and low overall clinical risk may be monitored. |
| Does PI-RADS 4 usually require biopsy? | Biopsy is generally appropriate in a diagnostic setting because clinically significant cancer is sufficiently likely. |
| Does PI-RADS 5 still need biopsy? | Usually yes. MRI cannot determine the histological cancer grade with enough certainty for treatment planning. |
| What is a transperineal biopsy? | A biopsy in which the needle reaches the prostate through the perineal skin. |
| What is a transrectal biopsy? | A biopsy in which the needle passes through the rectal wall into the prostate. |
| Which biopsy route has lower infection risk? | Transperineal biopsy has the lower infectious risk and is currently preferred by the EAU for that reason and for antibiotic stewardship. |
| Do all guidelines require transperineal biopsy? | No. EAU guidance strongly favors transperineal biopsy, while AUA guidance allows either transperineal or transrectal routes. |
| Can transperineal biopsy be done under local anesthesia? | Yes. Modern transperineal biopsy can often be performed under local anesthesia. |
| What is MRI-targeted prostate biopsy? | Biopsy cores are specifically directed into a suspicious prostate lesion previously identified on MRI. |
| What is fusion biopsy? | A targeting technique in which software aligns MRI with real-time ultrasound to guide the biopsy needle toward the MRI lesion. |
| Is fusion always better than cognitive targeting? | No clear universal superiority has been established; experience and image quality matter substantially. |
| How many cores are taken from an MRI lesion? | The number varies by target and strategy. AUA guidance recommends at least two cores per suspicious MRI target. |
| How many cores are in a systematic biopsy? | A standard non-targeted systematic biopsy traditionally uses about 12 appropriately distributed cores. |
| What is perilesional sampling? | Additional tissue is obtained immediately around the MRI target to account for targeting error and microscopic cancer extending beyond the visible lesion. |
| Why not biopsy only the MRI lesion? | Some significant cancers exist outside MRI targets, and MRI can underestimate the lesion’s microscopic boundaries. |
| Does systematic biopsy still have a role? | Yes in selected diagnostic and treatment-planning situations, although MRI-targeted and regional strategies increasingly reduce reliance on indiscriminate systematic sampling. |
| Does biopsy hurt? | Most procedures use local anesthesia. Pressure and brief discomfort can occur, and experience varies between patients and techniques. |
| Is blood in urine normal afterward? | Minor hematuria is common and usually resolves on its own. |
| Is blood in semen normal? | Yes. Red, brown or rust-colored semen can persist for several weeks after biopsy. |
| Can prostate biopsy cause infection? | Yes. Infection risk is substantially lower with the transperineal route but is not literally zero. |
| Can biopsy cause sepsis? | Sepsis is an uncommon but serious complication, particularly relevant to transrectal biopsy. Fever and rigors after biopsy require urgent medical assessment. |
| Can biopsy cause urinary retention? | Yes. Temporary prostate swelling can occasionally prevent urination and require catheter drainage. |
| Does prostate biopsy spread cancer? | Routine biopsy has not been shown to meaningfully spread prostate cancer. Needle-tract seeding has only been described exceptionally. |
| Can biopsy affect erections? | Temporary erectile changes can occur in some men, often alongside pain, anxiety or inflammation; persistent dysfunction is not an expected routine outcome. |
| What does the pathologist report? | Whether cancer is present, cancer type, Gleason patterns, ISUP Grade Group, tumor extent in cores and selected adverse histological features. |
| What is Grade Group? | A 1-to-5 pathology grading system derived from Gleason patterns that reflects prostate-cancer architecture and aggressiveness. |
| Can a negative biopsy miss cancer? | Yes. Biopsy samples only part of the prostate, so persistent high-risk MRI or PSA findings can justify further evaluation. |
| What happens after a negative biopsy? | Follow-up depends on PSA, PSA density, MRI findings, pathology, family/genetic risk and how well the suspicious region was sampled. |
| What happens after a positive biopsy? | PSA, Grade Group, tumor volume, stage, health and patient preferences are combined to determine whether surveillance, local treatment or systemic treatment evaluation is appropriate. |
ΣKey Clinical Takeaways
- A prostate biopsy removes tissue rather than merely imaging or measuring the prostate.
- Microscopic examination of biopsy tissue is the usual method for confirming prostate cancer.
- PSA and MRI estimate cancer probability but do not replace tissue diagnosis when biopsy is indicated.
- Modern diagnostic pathways usually perform prostate MRI before biopsy when organ-confined cancer is suspected.
- Not every high PSA requires immediate biopsy.
- Not every MRI lesion requires biopsy.
- Selected men with PI-RADS 1–2 and reassuring PSA density can often be monitored.
- Selected very-low-risk PI-RADS 3 lesions can also be monitored.
- PI-RADS 4–5 lesions generally move the pathway toward tissue sampling.
- Biopsy route and biopsy sampling strategy are separate decisions.
- Transperineal biopsy passes the needle through perineal skin.
- Transrectal biopsy passes the needle through the rectal wall.
- EAU currently strongly recommends the transperineal route because of lower infectious risk and antibiotic stewardship.
- AUA guidance permits either transperineal or transrectal biopsy.
- Both routes can be performed with local anesthesia.
- Transperineal biopsy can provide particularly useful access to anterior prostate tissue.
- Transrectal biopsy requires greater attention to bowel-derived infection prevention.
- Systematic biopsy samples predefined anatomical regions.
- A traditional systematic biopsy uses approximately 12 appropriately distributed cores.
- MRI-targeted biopsy samples a lesion identified on prostate MRI.
- MRI targets can be sampled cognitively, with MRI-ultrasound fusion software or by direct in-bore MRI guidance.
- No targeting technology has proven universally superior in every clinical setting.
- AUA recommends at least two cores per suspicious MRI target.
- Current EAU guidance recommends targeted plus perilesional sampling for PI-RADS 4 or higher lesions.
- Perilesional cores compensate for imperfect targeting and MRI underestimation of microscopic tumor extent.
- Systematic sampling can still detect clinically significant cancers outside MRI targets.
- No single biopsy scheme is ideal for every diagnostic and treatment-planning scenario.
- The 2026 ProBIOPSY consensus supports indication-specific biopsy planning.
- Additional contralateral sampling may still be important when assessing some candidates for focal therapy.
- Biopsy cores should remain site-labeled so pathology can be correlated with MRI targets.
- Pathology reports whether cancer is present and identifies the histological type.
- Pathology determines Gleason patterns and ISUP Grade Group.
- Gleason 3+4 and 4+3 are biologically different despite both totaling 7.
- Modern pathology also reports pattern 4 percentage in Gleason 7 biopsies.
- Cribriform and intraductal carcinoma are important adverse histological findings.
- The number and extent of positive cores provide information about sampled tumor burden.
- Grade Group is not the same as cancer stage.
- A negative biopsy does not guarantee that every part of the prostate is cancer-free.
- Persistent PI-RADS 4–5 findings after a negative biopsy may require MRI review, pathology review or repeat targeted evaluation.
- Minor blood in urine is common after biopsy.
- Blood in semen can persist for several weeks.
- Urinary retention can occasionally occur and may require temporary catheterization.
- Infectious risk is lower with transperineal biopsy than transrectal biopsy.
- Fever, shaking chills, inability to urinate or heavy bleeding after biopsy require prompt medical assessment.
- Routine needle biopsy has not been shown to meaningfully spread prostate cancer.
- A positive biopsy does not automatically dictate one treatment; subsequent decisions depend on Grade Group, PSA, stage, cancer extent, health and patient preferences.
Clinical bottom line: prostate biopsy is the point at which cancer suspicion becomes microscopic evidence. PSA may signal risk, MRI may locate a suspicious lesion and PI-RADS may quantify imaging suspicion, but biopsy physically samples the tissue so a pathologist can determine whether cancer is present and how it is graded. Modern biopsy is increasingly MRI-directed and tailored to the individual indication. The transperineal route is now preferred by current EAU guidance because of its lower infectious risk, while targeted and perilesional cores improve sampling of MRI-visible disease. The best biopsy is therefore not simply the procedure with the most needles—it is the strategy that answers the clinical question with sufficient tissue while minimizing unnecessary sampling and harm.
Medical disclaimer: This article provides general medical education about prostate biopsy. The need for biopsy, biopsy route, anesthesia, antibiotic strategy, management of blood-thinning medicines and number of tissue cores depend on individual medical history, MRI findings, PSA density, infection risk, previous biopsy results and local clinical protocols. Do not stop prescription blood thinners or take antibiotics for biopsy without instructions from the treating medical team.
For the complete diagnostic sequence leading to biopsy, see How Prostate Cancer Is Diagnosed. If the biopsy was recommended because MRI found an abnormal region, review What Is a Prostate Lesion?, What Is a Prostate MRI?, Multiparametric Prostate MRI and PI-RADS Scoring. For the blood-test side of the decision, see PSA Testing, PSA Density and What Happens After a High PSA?. For the broader disease pathway, return to the Prostate Cancer hub. The next guide compares transperineal and transrectal prostate biopsy directly, including infection risk, anesthesia, cancer detection, anterior-prostate access and recovery.
Evidence Sources
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: MRI-before-biopsy recommendations, systematic and MRI-targeted biopsy strategies, targeted plus perilesional sampling, transperineal versus transrectal routes, infection prevention and pathology reporting.
- Chernysheva D, Di Bello F, Avesani G, et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. European Urology. 2026;90(3):212–224.
- ProBIOPSY International Consensus — contemporary standards for MRI-informed targeted and perilesional prostate biopsy and treatment-planning considerations.
- American Urological Association / Society of Urologic Oncology — Early Detection of Prostate Cancer: biopsy technique, MRI targeting, minimum target cores and transrectal versus transperineal access.
- National Cancer Institute — PSA testing and the role of transperineal or transrectal needle biopsy after persistent prostate-cancer suspicion.
- National Cancer Institute — Prostate Cancer Treatment PDQ: prostate biopsy, pathological diagnosis, Gleason score and Grade Group.
- Mayo Clinic — Prostate biopsy: patient preparation, biopsy routes, common bleeding, hematospermia, urinary difficulty and infection warning signs.
